Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Thrombogenics Outlicenses Stem Cell Medium Technology to Millipore

  • ThromboGenics will exclusively license its technology to Millipore for the company to produce its stem cell culture medium, RESGRO™.

     

    Under this global license agreement agreement, ThromboGenics will license to Millipore its patents, data, and know-how for the manufacturing, development, and evaluation of RESGRO. Millipore will assume responsibility for the exclusive production and sales of the medium as well as all future costs. ThromboGenics will receive upfront and milestone payments and will earn double digit royalties on Millipore's sales.


    The technology for producing RESGRO was originally developed by the ThromboGenics drug discovery team as part of its efforts to identify several of its drug discovery candidates currently in clinical trials.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »